Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 5/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.56 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 7/20 | 0.54 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.51 |
| ▸ | APLNR | P35414 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.49 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433316 | 0.96 | CAPN1 (0.61) | KISS1RCAPN1CTSBIL23RCXCR4 | |
| SCHEMBL31433256 | 0.91 | IL23R (0.62) | IL23RCXCR4C5AR1 | |
| SCHEMBL29463744 | 0.90 | KISS1R (0.60) | KISS1RCAPN1CTSBIL23RCXCR4 | |
| SCHEMBL31433287 | 0.88 | KISS1R (0.59) | KISS1RIL23RCXCR4MAPK8MAPK9 | |
| SCHEMBL38652302 | 0.88 | CXCR4 (0.59) | KISS1RCAPN1CTSBCXCR4NTSR2 | |
| SCHEMBL29463717 | 0.87 | CAPN1 (0.63) | KISS1RCAPN1CTSBIL23RCXCR4 | |
| SCHEMBL34461092 | 0.87 | CXCR4 (0.59) | KISS1RCAPN1CTSBCXCR4NTSR2 | |
| SCHEMBL31620052 | 0.87 | C5AR1 (0.57) | KISS1RIL23RCXCR4NTSR2NTSR1 | |
| SCHEMBL30780077 | 0.85 | CTSL (0.55) | KISS1RCAPN1CTSBCXCR4MAPK8 | |
| SCHEMBL34461111 | 0.85 | DPP3 (0.56) | KISS1RCAPN1CTSBIL23RCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | KISS1R 1078/4885CAPN1 3160/4885CTSB 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.